Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Gil

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Expert Review of Anticancer Therapy|December 16, 2014
Cancer and the microbiome: potential applications as new tumor biomarkerKhan Shahanavaj, Ignacio Gil-Bazo, Marta Castiglia, et al.
Oncotarget|February 27, 2016
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceSimona Taverna, Marco Giallombardo, Ignacio Gil-Bazo, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2012
External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcomeRafael Martínez-Monge, Marta Moreno, Raquel Ciérvide, et al.
Clinical Genitourinary Cancer|October 17, 2013
Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implicationsMariano Ponz-Sarvisé, Eduardo Castañón, Angel Panizo-Santos, et al.
Journal of Translational Medicine|January 15, 2013
Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapyEduardo Castañon, Joaquim Bosch-Barrera, Inés López, et al.
Nutrients|July 9, 2022
Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 LockdownPatricia Yárnoz-Esquíroz, Ana Chopitea, Laura Olazarán, et al.
Frontiers in Oncology|December 22, 2025
CD26 as a potential therapeutic target for lung adenocarcinomaWolfgang Jungraithmayr, Birte Ohm, Martina Haberecker, et al.
Clinical Genitourinary Cancer|December 25, 2012
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancerIgnacio Gil-Bazo, Estefanía Arévalo, Ainhoa Castillo, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Journal of Translational Medicine|April 15, 2014
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexedEstefanía Arévalo, Eduardo Castañón, Inés López, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Expert Review of Anticancer Therapy|December 16, 2014
Cancer and the microbiome: potential applications as new tumor biomarkerKhan Shahanavaj, Ignacio Gil-Bazo, Marta Castiglia, et al.
Oncotarget|February 27, 2016
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceSimona Taverna, Marco Giallombardo, Ignacio Gil-Bazo, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2012
External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcomeRafael Martínez-Monge, Marta Moreno, Raquel Ciérvide, et al.
Clinical Genitourinary Cancer|October 17, 2013
Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implicationsMariano Ponz-Sarvisé, Eduardo Castañón, Angel Panizo-Santos, et al.
Journal of Translational Medicine|January 15, 2013
Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapyEduardo Castañon, Joaquim Bosch-Barrera, Inés López, et al.
Nutrients|July 9, 2022
Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 LockdownPatricia Yárnoz-Esquíroz, Ana Chopitea, Laura Olazarán, et al.
Frontiers in Oncology|December 22, 2025
CD26 as a potential therapeutic target for lung adenocarcinomaWolfgang Jungraithmayr, Birte Ohm, Martina Haberecker, et al.
Clinical Genitourinary Cancer|December 25, 2012
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancerIgnacio Gil-Bazo, Estefanía Arévalo, Ainhoa Castillo, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Journal of Translational Medicine|April 15, 2014
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexedEstefanía Arévalo, Eduardo Castañón, Inés López, et al.
Pageof 15